Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Oct 27, 2024; 16(10): 1188-1198
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1188
Complement activation targeted inhibitor C2-FH ameliorates acetaminophen-induced liver injury in mice
Chun-Mei Li, Tian Sun, Mou-Jie Yang, Zhi Yang, Qing Li, Jia-Lin Shi, Chong Zhang, Jun-Fei Jin
Chun-Mei Li, Tian Sun, Mou-Jie Yang, Zhi Yang, Qing Li, Jia-Lin Shi, Chong Zhang, Jun-Fei Jin, Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, the Affiliated Hospital of Guilin Medical University, Guilin 541001, Guangxi Zhuang Autonomous Region, China
Chun-Mei Li, Tian Sun, Mou-Jie Yang, Zhi Yang, Qing Li, Jia-Lin Shi, Chong Zhang, Jun-Fei Jin, Guangxi Health Commission Key Laboratory of Basic Research in Sphingolipid Metabolism Related Diseases, the Affiliated Hospital of Guilin Medical University, Guilin 541001, Guangxi Zhuang Autonomous Region, China
Chun-Mei Li, Tian Sun, Zhi Yang, Qing Li, Chong Zhang, Jun-Fei Jin, China-United States Lipids in Health and Disease Research Center, Guilin Medical University, Guilin 541001, Guangxi Zhuang Autonomous Region, China
Chun-Mei Li, Tian Sun, Zhi Yang, Qing Li, Chong Zhang, Jun-Fei Jin, Laboratory of Hepatobiliary and Pancreatic Surgery, the Affiliated Hospital of Guilin Medical University, Guilin 541001, Guangxi Zhuang Autonomous Region, China
Co-first authors: Chun-Mei Li and Tian Sun.
Co-corresponding authors: Chong Zhang and Jun-Fei Jin.
Author contributions: Li CM, Sun T, Zhang C, Jin JF conceptualized and designed the study; Li CM, Sun T, Yang MJ, Yang Z, Li Q, Shi JL conducted the experiments and analyzed the data; Li CM and Sun T wrote the first draft of the paper; Zhang C and Jin JF revised the paper. All authors have read and approve the final version. Li CM and Sun T contributed equally to this work, so they are qualified to be joint first authors. Zhang C and Jin JF made significant contributions to the completion of this article. Specifically, Zhang C played a pivotal role in key areas, including experimental design, data collection and analysis, as well as the writing and submission processes. Jin JF provided research funding, contributed to experimental design, and oversaw the research, writing, revision, and submission processes of the paper. He has agreed to accept responsibility for all aspects of the research work and to ensure that any questions regarding the accuracy or completeness of any part of the paper are thoroughly investigated and resolved. Although these contributions may not be fully reflected in the paper, they are essential to the reliability and quality of the research. Thus, both Zhang C and Jin JF were instrumental in the project's completion and served as corresponding authors.
Supported by Natural Science Foundation of Guangxi, No. 2020GXNSFDA238006; Special Fund of the Central Government Guiding Local Scientific and Technological Development by Guangxi Science and Technology Department, No. GuikeZY21195024; and Research Enhancement Project for Junior Faculty in Higher Education Institutes of Guangxi, No. 2018KY0419.
Institutional review board statement: This article does not pertain to human samples or clinical trials; therefore, no approval forms are necessary.
Institutional animal care and use committee statement: The study was reviewed and approved by the institutional animal care guidelines approved by the Experimental Animal Ethical Committee of Guilin Medical University (Approval No. GLMC-IACUC-20241021).
Conflict-of-interest statement: All the authors declare that they have no conflict of interest to disclose.
Data sharing statement: Data supporting the findings of this study are available from the corresponding authors (changliangzijin@163.com) upon reasonable request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun-Fei Jin, PhD, Professor, Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, the Affiliated Hospital of Guilin Medical University, No. 15 Lequn Road, Guilin 541001, Guangxi Zhuang Autonomous Region, China. changliangzijin@163.com
Received: April 28, 2024
Revised: September 12, 2024
Accepted: September 19, 2024
Published online: October 27, 2024
Processing time: 175 Days and 20.6 Hours
Abstract
BACKGROUND

Complement activation is recognized as an important factor in the progression of liver damage caused by acetaminophen (APAP). However, the role of the complement inhibitor C2-FH in APAP-induced liver injury remains unclear.

AIM

To explore C2-FH in protecting against APAP-induced liver injury by inhibiting complement activation.

METHODS

A model of APAP-induced liver injury was used to study the protective effect of C2-FH on liver injury. C2-FH was administered through intraperitoneal injection 30 minutes after APAP treatment. We detected the effects of C2-FH on liver function, inflammatory response and complement activation. Additionally, RNA-sequencing (RNA-Seq) analysis was conducted to understand the mechanism through which C2-FH provides protection against APAP-induced liver injury.

RESULTS

C2-FH inhibited the increase in serum alanine aminotransferase activity, aspartate aminotransferase activity and lactate dehydrogenase, and reduced liver tissue necrosis caused by APAP. Moreover, it attenuated the inflammatory response and inhibited complement activation in APAP-induced liver injury. RNA-Seq analysis provided additional explanations for the protective role of C2-FH against APAP-induced liver injury.

CONCLUSION

C2-FH attenuates APAP-induced liver injury by inhibiting complement activation.

Keywords: C2-FH; Complement; Complement activation; Acetaminophen-induced liver injury; Inflammation

Core Tip: Acetaminophen (APAP) is frequently utilized as a non-prescription medication for reducing fever and relieving pain. However, excessive intake of APAP may result in acute liver injury, liver failure and even death. This study found that C2-FH improved APAP-induced liver injury by alleviating liver tissue injury, inflammation and reducing the accumulation of complement activated products. Our research provided evidence that C2-FH shows potential as a possible treatment for APAP-induced liver injury.